



Contact: J. Robert Paulson, CEO
(651) 484-6095

FOR IMMEDIATE RELEASE

André de Bruin Appointed Chair of NxThera Board of Directors

St. Paul, Minn. (Jan. 30, 2012) – NxThera, Inc., a St. Paul-based, privately held medical device company that developed the Rezūm™ vapor ablation system to treat a variety of endourology conditions, beginning with benign prostatic hyperplasia (BPH), today announced the appointment of André de Bruin as chair of the company’s board of directors.

Mr. de Bruin has served as a director of NxThera since November 2009, and has more than 35 years of global healthcare industry experience spanning the medical device, bio-pharmaceutical and diagnostics markets. In 2004, Mr. de Bruin retired as executive chairman of Quidel Corporation's board of directors after serving as the company's chief executive officer from 1998 until 2001. Mr. de Bruin was chairman, president and chief executive officer of Somatogen and was elected chairman in 1996. Prior to joining Somatogen, Mr. de Bruin served as chairman, president and chief executive officer of Boehringer Mannheim Corporation, a global healthcare company subsequently acquired by Hoffman-La Roche. Mr. de Bruin has provided advisory services for Ferrer, Freeman and Company LLC, and served on various boards of directors.

“We are very pleased to have André assume this board leadership role,” said Bob Paulson, president and chief executive officer of NxThera. “Our entire organization will benefit from André’s extensive global healthcare knowledge and experience as we begin our clinical studies, prepare for international and U.S. commercialization, and leverage our novel vapor ablation technology platform into other new and compelling clinical endourology indications.”

About NxThera

NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The Company’s Rezūm System delivers vapor directly to the prostate to reduce the tissue volume that causes urinary obstruction in a simple, office-based procedure designed to take only minutes, with minimal discomfort, and resulting in rapid and significant improvements in urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States. For more information on NxThera, visit www.nxthera.com or call (651) 484-0219.